Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

By sjmartinez • January 27, 2023

Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023 Jan 23:S2213-2600(22)00492-1. doi: 10.1016/S2213-2600(22)00492-1. Epub ahead of print. PMID: 36702146.

Tags: clinical immunology and allergy, Publications

Developing remote patient monitoring infrastructure using commercially available cloud platforms

Cao M, Ramezani R, Katakwar VK, Zhang W, Boda D, Wani M, Naeim A. Developing remote patient monitoring infrastructure using commercially available cloud platforms. Front[...]

A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide

Dao KT, Dhillon A, Uddin SS, Eppanapally S, Lai H. A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide. J[...]

Advancements in Spinal Cord Injury Rehabilitation

Eapen BC. Advancements in Spinal Cord Injury Rehabilitation. Phys Med Rehabil Clin N Am. 2025 Feb;36(1):xiii-xiv. doi: 10.1016/j.pmr.2024.09.002. Epub 2024 Oct 18. PMID: 39567042.